BOTHELL, Wash.--(BUSINESS WIRE)--June 5, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN - News) today reported data from its phase I clinical trial of SGN-40 in non-Hodgkin's lymphoma at the American Society of Clinical Oncology (ASCO) 42nd Annual Meeting being held in Atlanta June 2-6. SGN-40 induced objective responses in five patients and was well tolerated at doses up to 8 milligrams per kilogram. The company is completing treatment of the final cohort of patients and plans to advance SGN-40 into phase II clinical trials during the second half of 2006.
